Washington | The American company Moderna announced on Tuesday that it had started trials of its COVID-19 vaccine on thousands of children aged 6 months to 11 years, a new step considered necessary to arrive at an end to the pandemic.
If they constitute a significant part of the population, children are however less exposed to severe cases of the disease, while transmitting it less for the youngest among them. Their vaccination has thus far not been a priority.
Currently, Pfizer’s COVID vaccine is licensed for people aged 16 and over, and Moderna and Johnson & Johnson’s for those 18 and over.
The three American companies have already started, sometimes for several months, clinical trials to test their vaccine on adolescents (from 12 years old). AstraZeneca, for its part, is studying the effect of its vaccine from the age of 6.